CLINICAL AND EXPERIMENTAL RHEUMATOLOGY is a prestigious journal published by CLINICAL & EXPER RHEUMATOLOGY, dedicated to advancing the field of rheumatology and immunology. With a rich history dating back to 1983, the journal serves as a critical platform for researchers, clinicians, and professionals seeking to disseminate and discuss innovative findings in these rapidly evolving areas. Featuring an impressive Q2 ranking in both Immunology and Allergy, as well as Rheumatology, this journal is recognized for its high-quality contributions, placing it among the top tier of academic publications. Operating without an open access model, CLINICAL AND EXPERIMENTAL RHEUMATOLOGY is headquartered in Pisa, Italy, and publishes articles that undergo rigorous peer review to ensure excellence in research. This journal is an invaluable resource for those dedicated to improving patient outcomes through evidence-based practice in rheumatology, immunology, and related fields.

Theranostics is a premier journal in the field of Medicine and Pharmacology, published by IVYSPRING INT PUBL. With its commitment to open access since 2011, it facilitates the widespread dissemination of innovative research, fostering collaboration and advancements in therapeutic diagnostics. The journal proudly holds a Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, Toxicology and Pharmaceutics, as of 2023, showcasing its esteemed position within the scientific community. Recognized globally, it ranks in the top 1%, with Scopus rankings placing it as 4th out of 398 in Medicine and 1st out of 43 in Pharmacology. Theranostics serves as a crucial platform for researchers, professionals, and students to explore cutting-edge developments as it converges multidisciplinary approaches to enhance patient care and treatment efficacy. With a focus on bridging experimental research and clinical applications, the journal is instrumental in shaping future therapies and diagnostic strategies.

Molecular Diagnosis & Therapy, published by ADIS INT LTD, is a premier journal dedicated to the cutting-edge fields of genetics, molecular medicine, and pharmacology. With a strong emphasis on the translation of molecular insights into innovative therapeutic strategies, this journal serves as a vital resource for researchers, clinicians, and students aiming to stay at the forefront of medical and scientific advancements. The journal boasts an impressive standing in its categories, holding a Q1 ranking in Genetics, Medicine (miscellaneous), and Pharmacology, alongside a Q2 classification in Molecular Medicine for 2023, reflecting its influential contributions to the scientific community. Indexed in Scopus, it occupies distinct positions in its respective fields, ranked #77 in Genetics and Pharmacology, and #53 in Molecular Medicine, highlighting its robust impact factor and scholarly influence. Although it is not open access, the journal ensures widespread dissemination of valuable research, promoting enhanced understanding of molecular diagnostic techniques and therapeutic interventions. Since its inception in 2001, and continuing through to 2024, Molecular Diagnosis & Therapy remains an essential platform for disseminating vital research findings, fostering academic collaboration, and driving forward the dialogue in molecular diagnostics and treatment methodologies.

EBioMedicine is an esteemed open-access journal published by ELSEVIER, dedicated to advancing the fields of biochemistry, genetics, and molecular biology, as well as medicine. Since its inception in 2014, EBioMedicine has established itself as a prominent platform for disseminating high-quality research, evidenced by its impressive rankings in Scopus, where it holds a Q1 category in both Biochemistry, Genetics and Molecular Biology and Medicine for 2023. With an exceptional impact factor that places it in the top percentiles (97th in Medicine and 93rd in Biochemistry), the journal is recognized for its rigorous peer-review process and its commitment to fostering scientific collaboration. Open access since its launch, EBioMedicine ensures that groundbreaking research is readily available to researchers, professionals, and students worldwide, enhancing knowledge dissemination and driving innovation in these crucial fields. For those seeking to stay at the forefront of biomedical research, EBioMedicine is an invaluable resource.

Molecular Biomedicine is a prestigious peer-reviewed journal published by SpringerNature, dedicated to advancing the fields of molecular biology and molecular medicine. With a commendable Q1 ranking in both categories for 2023, this journal stands out for its rigorous exploration of the biochemical processes underlying health and disease. Operating out of Germany, Molecular Biomedicine aims to provide comprehensive insights into cutting-edge research, facilitating interdisciplinary collaboration among researchers, healthcare professionals, and students alike. The journal's impact is reflected in its Scopus rankings, placing it in the upper echelons of the fields of biochemistry, genetics, and molecular biology. As an open access platform, it commits to disseminating knowledge widely, ensuring that pivotal discoveries are accessible to all. Researchers looking to publish in a dynamic environment that prioritizes innovation and application in the biomedical sciences will find Molecular Biomedicine an ideal outlet for their work.

The Biomedical Journal, published by ELSEVIER, serves as a premier platform for disseminating groundbreaking research in the field of medicine, specifically within the Q1 category of Medicine (Miscellaneous). With the ISSN 2319-4170 and E-ISSN 2320-2890, this Open Access journal has been committed to advancing biomedical science since its inception in 2002. With an impressive Scopus rank of #31 out of 636 in General Medicine and a notable placement in the 95th percentile, the journal provides valuable insights and rigorous studies that contribute significantly to the medical community. Based in the Netherlands at RADARWEG 29, 1043 NX AMSTERDAM, the journal is highly regarded for its timely and diverse range of articles, fostering collaboration and innovation amidst researchers, professionals, and students alike. The ongoing engagement in the journal's converged years from 2012 to 2024 underscores its commitment to keeping pace with the evolving landscape of biomedical research, making it an essential resource for those seeking to stay at the forefront of medical advancements.

The Journal of Molecular Diagnostics is a premier publication in the fields of molecular medicine and pathology, published by Elsevier Science Inc. With an impressive impact factor and recognized as a Q1 journal in both Molecular Medicine and Pathology and Forensic Medicine, this journal is dedicated to advancing the understanding and application of molecular diagnostics in clinical practice. The journal features rigorous peer-reviewed research, comprehensive reviews, and cutting-edge methodologies that highlight novel diagnostic tests and biomarkers. Researchers, professionals, and students in the biomedical sciences are invited to explore its diverse array of articles and contribute to a growing body of knowledge critical for innovation in healthcare delivery. Located in the Netherlands, the journal has secure its position among the top-tier journals with its recent Scopus ranking of 20th out of 208 in Medicine Pathology and Forensic Medicine, reflecting a strong percentile ranking of 90th. With coverage spanning from 1999 to 2024, the Journal of Molecular Diagnostics remains a vital resource for anyone committed to the future of molecular research and diagnostics.

BIOMARKERS is a distinguished journal published by Taylor & Francis Ltd, focusing on the critical intersection of biochemistry, clinical biochemistry, and health-related toxicology. With a robust history of publication since 1996 and ongoing contributions through to 2024, the journal serves as a vital platform for researchers, professionals, and students keen on exploring innovative biomarker research that spans various domains within the life sciences. The journal is currently ranked in the Q3 quartile in key areas such as Biochemistry and Health, demonstrating its reputation in the scientific community. Although it operates under a subscription model, BIOMARKERS remains an essential resource for advancing knowledge on biomarkers in health and disease, reflecting the latest advancements and methodologies within the rapidly evolving landscape of biomedical research. Researchers looking to publish in this influential journal can expect a rigorous peer-review process aimed at ensuring the dissemination of high-quality scientific inquiry.

Biomarker Insights, published by SAGE Publications Ltd, is a leading open-access journal dedicated to advancing the field of biomarker research and its applications in health and disease. With an ISSN of 1177-2719 and an E-ISSN of 1177-2719, this journal has been at the forefront of disseminating high-quality scientific findings since its inception in 2006. Based in New Zealand, it has achieved a notable impact within the academic community, ranking in Q2 for Biochemistry (medical) and Molecular Medicine, and Q1 in Pharmacology as of 2023. This positions Biomarker Insights as a critical resource for researchers, professionals, and students alike, looking to explore innovative methodologies and applications in biomarker discovery and validation. With a commitment to open access, the journal ensures that groundbreaking research is readily available to the global community, fostering collaboration and innovation in the ever-evolving field of biomedical sciences.

Immunity, Inflammation and Disease is a premier open-access journal published by WILEY, dedicated to advancing the field of immunology and allergy. Launched in 2013, this journal has established itself as a significant platform for researchers and professionals to disseminate high-quality research findings and innovative insights that address critical issues in immune responses and inflammatory diseases. With an impact factor that reflects its growing influence and a current ranking in Q3 for Immunology and Q2 for Immunology and Allergy, this journal serves a diverse audience keen on exploring cutting-edge developments. Researchers are encouraged to submit their work to share their findings with a global reach, foster collaboration, and enhance the understanding of immune mechanisms and therapeutic strategies. Accessible since its inception, Immunity, Inflammation and Disease is committed to open science, ensuring that vital research is freely available for the advancement of knowledge within the academic community and beyond.